home > news > detailed info

Haselmeier Relies on DQIQOQ Qualified Testing Machines and Zwicks Materials Testing Laboratory


Ensuring correct dosing

An autoinjector is a medical instrument with which liquid medication can be administered. It is subject to strict quality controls. The correct injection and proper dose of medicine (for example, insulin) are vital to achieve the best therapeutic success. That is why pharmaceutical manufacturers strive to achieve a high level of automation in autoinjector technology. Haselmeier develops and produces these types of high-quality self injection devices with different levels of automation.

The company tasked the Zwick Materials Testing Laboratory to quickly perform tests on 160 disposable pens with variable injection doses that are used with 3 ml carpules. The tests were conducted in the Zwick Materials Testing Laboratory with a materials testing machine featuring a torsion drive. In line with Haselmeier's high quality standards, a testing machine was used that was qualified to DQ/IQ/OQ requirements and confirmed as suitable to perform the tests on the basis of a measurement system analysis (MSA1 and analysis of measurement system capabilities and support for MSA2).

DQ IQ OQ qualification

That is why comprehensive DQ/IQ/OQ documentation about the system's the mechanical features, including the load cell and test fixtures used, was created for this machine in Zwick's Materials Testing Laboratory. With this documentation and a checklist in accordance with the customer's requirements, the qualification was conducted by an experienced Zwick service technician. This was followed by a successful MSA1 and MSA2 measurement system analysis, which more than surpassed Haselmeier's demanding specifications.

Finally, the tests were run in the Zwick Materials Testing Laboratory: A total of 160 pens were tested (destructive and non-destructive). For example, misapplication was simulated and excessive torque forces were applied to the pens. The amount of torque needed to break the pen was measured.

Together with the test results, Haselmeier received expanded documentation containing the DQ/IQ/OQ qualification and measurement system analyses that were performed by Zwick prior to the tests. This documentation, with almost 7,800 points, make it possible for third parties to reproduce who did what and when with the testing machine.

"We had absolute confidence in Zwick's Materials Testing Laboratory when it came to flexibility, speed, and reliability. In particular, the ability to conduct tests with a DQ/IQ/OQ-qualified testing machine while being present on site for the tests was very important," explains Ingo Giesecke, Laboratory Manager at Haselmeier in Stuttgart.
phone +49 7305 100
email August-Nagel-Strasse 11, 89079, ULM, Germany
Print this page
Send to a friend
News and Press Releases

PCI Pharma Services Announces Agreement to Acquire Sherpa Clinical Packaging

Philadelphia, USA – September 10, 2018 Leading global biopharmaceutical outsourcing services provider PCI Pharma Services (PCI) is pleased to announce the acquisition of San Diego-based Sherpa Clinical Packaging (Sherpa), which expands PCI’s U.S. operations to the West Coast. The acquisition of Sherpa, a provider of clinical trial supply services, further strengthens PCI’s position as a leader in outsourced clinical trial support services. The addition of Sherpa’s capabilities also enables PCI to better support customers from early phases of clinical development through to commercial launch.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

Industry Events

CPhI & P-MEC India 2018

12-14 December 2018, India Expo Mart, New Delhi, India

CPhI & P-MEC India (December 12-14, 2018) – organised by UBM (part of Informa PLC) – announces that the 12th edition of Asia’s largest Pharma exhibition is moving to the India Expo Mart, New Delhi. The new venue will see the exhibition now hosted in a single venue, bringing it closer to the Indian regulatory and legislative capital. New Delhi is also the country’s main international transport hub and will encourage an increased international attendance. In total, more than 50,000 people from 122 countries are expected, along with nearly 1,500 exhibitors.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement